Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLL.L Regulatory News (CLL)

  • There is currently no data for CLL

Year end trading update

19 Jan 2009 07:00

RNS Number : 8037L
Cello Group plc
19 January 2009
 



19 January 2009

  

Cello Group plc

Year end trading update

 

Cello Group plc ("Cello" or the "Group", AIM: CLL), the leading independent market research and consulting group, today provides the following trading update for the year ended 31 December 2008

 

Since the announcement of the Group's interim results in early September, trading has tightened across certain sectors of Cello's broad domestic and international client base As a result, the Board anticipates that the Group's results for the full year will be at the lower end of market expectations.

There has been very strong cash conversion in the second half of 2008, as a result of which the Board expects to report year end net debt of less than £10.5m, significantly below consensus expectations.

The Group has agreed enlarged banking facilities with the revolving credit facility now increased from £18.0m to £20.0m for 2009, amortising to £17.0m for 2010. The overdraft facility of £2.0m has also been renewed and is now a multi-currency arrangement. The extra interest cost associated with these changes is expected to be broadly offset by lower overall interest rates.

The Group has re-estimated its total anticipated earn out obligations. These are now expected to be £15.2m compared with a previous estimate of £19.2m, with a minimum loan note component of £6.3m and the balance of £8.9m payable in shares. £7.8m of this total is anticipated to be settled in May 2009 with £3.2m payable in loan notes and £4.6m payable in shares. The balance of the total earn out commitment is payable between 2010 and 2013, with a loan note payment of £0.6m expected to be paid in 2010. The Group is entitled to pay an increased proportion of these total obligations in loan notes.

As well as the strong operating cash position and the reduced earn out provisions, the Group has continued to prudently reduce its cost base. In total over £2.0m of staff costs, on an annualised basis, have been removed during 2008.

Allan Rich, whose appointment as Acting Non-Executive Chairman was announced on September 2008has been confirmed as Non-Executive Chairman. Allan brings with him a wealth of experience of managing successfully through economic downturns.

 

The Group remains realistically cautious about the current outlook. While it is too early to give detailed guidance, numerous clients have indicated their intention to maintain their expenditure levels and the Group is seeing refreshed levels of spend from several of its public sector clients. In addition, all of Cello's investment start-up businesses are now trading profitably. All these factors, including the Group's strong financial position, should hold the Group in good stead in the current economic environment.

 

Cello expects to announce its preliminary results for the year ended 31 December 2008 on Tuesday 17 March 2009.

 

Enquiries

 

Cello Group 

 

Mark ScottChief Executive

020 7812 8460

Mark Bentley, Finance Director

 

Singer Capital Markets

 

Nicholas How

020 3205 7620

 

 

College Hill

 

Adrian Duffield/Rozi Morris

020 7457 2020

 

 

Notes to Editors (www.cellogroup.co.uk)

 

Cello is a market research and consulting group that listed on AIM in November 2004.

 

The Group's strategy is to create value for shareholders by building a world class market research business and a leading direct response business.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGUUACGUPBGAQ
Date   Source Headline
5th Jun 20181:24 pmRNSBlock listing Interim Review
29th May 20183:45 pmRNSDirector/PDMR Dealings and Total Voting Rights
9th May 20181:14 pmRNSResult of AGM
9th May 20187:00 amRNSAGM Statement
30th Apr 20182:58 pmRNSTotal Voting Rights
26th Apr 20189:45 amRNSChange of Name
25th Apr 20184:45 pmRNSChange of Name update
23rd Apr 201810:28 amRNSChange of name to Cello Health Group plc
16th Apr 20189:30 amRNSAnnual Report and Notice of AGM
22nd Mar 20187:00 amRNSFinal Results
27th Feb 20183:38 pmRNSTotal Voting Rights
18th Jan 20187:00 amRNSPre Close Trading Statement
23rd Nov 20173:54 pmRNSHolding(s) in Company
31st Oct 201711:16 amRNSTotal Voting Rights
26th Oct 20172:37 pmRNSDirector/PDMR Shareholding
29th Sep 20173:43 pmRNSGrant of Options
27th Sep 20174:59 pmRNSDirector/PDMR Shareholding
22nd Sep 201712:05 pmRNSDirector/PDMR Shareholding
20th Sep 20173:58 pmRNSHolding(s) in Company
20th Sep 201711:52 amRNSAdditional Block Listing of Ordinary Shares
20th Sep 20177:00 amRNSInterim Results
31st Aug 20173:19 pmRNSTotal Voting Rights
31st Jul 20173:06 pmRNSTotal Voting Rights
19th Jul 20177:00 amRNSPre Close Trading Statement
18th Jul 20177:00 amRNSAcquisition of Advantage Healthcare Inc
30th Jun 201712:31 pmRNSTotal Voting Rights
23rd Jun 201712:23 pmRNSHolding(s) in Company
14th Jun 201711:33 amRNSDirector/PDMR Shareholding
31st May 201710:27 amRNSTotal Voting Rights
18th May 20172:13 pmRNSHolding(s) in Company
10th May 20175:18 pmRNSHolding(s) in Company
9th May 20172:55 pmRNSResult of AGM
9th May 20177:00 amRNSAGM Statement
2nd May 20173:15 pmRNSIssue of Equity
13th Apr 20172:40 pmRNSAnnual Report and notice of Annual General Meeting
4th Apr 20175:44 pmRNSBlock listing Interim Review
31st Mar 201710:43 amRNSTotal Voting Rights
28th Mar 20173:03 pmRNSHolding(s) in Company
22nd Mar 20177:00 amRNSPreliminary Results
21st Feb 20171:30 pmRNSHolding(s) in Company
20th Feb 20173:19 pmRNSHolding(s) in Company
20th Feb 20179:29 amRNSTotal Voting Rights
17th Feb 201710:40 amRNSResult of General Meeting
1st Feb 20177:00 amRNSPlacing & Acquisition of Defined Health
19th Jan 20177:00 amRNSPre close trading statement
31st Oct 20163:58 pmRNSTotal Voting Rights
28th Oct 201611:37 amRNSDirector/PDMR Shareholding
12th Oct 20167:00 amRNSDirectorate Change
5th Oct 20164:32 pmRNSDirector/PDMR Shareholding
23rd Sep 20165:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.